Physician profile
Anith Pillai
NPI 1962759258
$101,818.60
in general payments reported to CMS, 2019-2025
31 companies · $7,963 in 2025
The $7,963 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,510 · 2020: $10K · 2021: $22K · 2022: $20K · 2023: $21K · 2024: $18K · 2025: $7,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Food and Beverage: $7,569 · Travel and Lodging: $7,071 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,938 · Consulting Fee: $3,400 · Entertainment: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,575.00 |
| Food and Beverage | $7,568.94 |
| Travel and Lodging | $7,070.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,937.50 |
| Consulting Fee | $3,400.00 |
| Entertainment | $235.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $39,678.15 | 2022-2025 | Zenlens, Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28,989.98 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $20,161.91 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Coopervision INC. | $3,419.56 | 2022-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Carl Zeiss Meditec, INC. | $1,443.63 | 2019-2021 | |
| Visioneering Technologies, INC. | $1,000.00 | 2024 | |
| Alcon Vision LLC | $764.21 | 2019-2023 | Argos, Total30 |
| Optos, INC. | $750.08 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $746.61 | 2021-2025 | Ce-Marked Kxla System, Idosetr |
| Carl Zeiss Meditec USA, INC. | $745.01 | 2021-2024 | Humphrey Hfa, Cirrus Hd-Oct |
| Dompe US, INC. | $595.48 | 2021-2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $468.55 | 2020-2022 | |
| Abbvie INC. | $430.81 | 2022-2024 | |
| Johnson & Johnson Vision Care, INC. | $378.20 | 2022-2024 | Acuvue |
| Biotissue Holdings INC. | $263.07 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $236.48 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $222.30 | 2024-2025 | Xdemvy |
| Notal Vision, INC. | $206.46 | 2022 | |
| Quidel Corporation | $202.84 | 2019 | |
| Harrow Eye, LLC | $198.65 | 2024-2025 | Vevye |
| Allergan, INC. | $156.20 | 2019-2022 | |
| Sight Sciences, INC. | $126.39 | 2019 | |
| Maculogix, INC. | $118.65 | 2019 | |
| Rxsight INC | $105.63 | 2022 | |
| Shire North American Group INC | $102.44 | 2019 | |
| Genzyme Corporation | $94.87 | 2019 | |
| Aerie Pharmaceuticals, INC. | $90.68 | 2019 | |
| Abb Con-Cise Optical Group LLC | $57.80 | 2021 | |
| Lombart Brothers, INC. | $22.28 | 2023 | Opd-III |
| Astellas Pharma US INC | $22.28 | 2025 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anith Pillai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.